Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver
Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver
复制标题
DOI：
10.1016/j.canlet.2005.12.040
复制
发表时间：
2007-01-08
期刊：
影响因子：
9.7
通讯作者：
Mazda, Osam
中科院分区：
文献类型：
--
作者：
Ishii, Michiaki;Iwai, Masaki;Mazda, Osam
转移性肝肿瘤是高度恶性的并且对常规疗法难以治疗。在重组 TRAIL (rTRAIL) 和次优剂量的放线菌素 D (ACD) 存在的情况下，TRAIL 抗性 CT-26 细胞在体外发生凋亡。可溶性 TRAIL (sTRAIL) 基因和 ACD 的共同给药抑制了 CT-26 的转移性肝肿瘤，显着诱导肿瘤细胞凋亡，而在单独接受 sTRAIL 基因或 ACD 的小鼠中没有显示出这种效果。使用次优剂量的抗癌药物进行 sTRAIL 基因治疗是治疗多发性肝转移的新策略。 (c) 2006 Elsevier Ireland Ltd. 保留所有权利。
Metastatic liver tumors are highly malignant and refractory to conventional therapies. TRAIL-resistant CT-26 cells underwent apoptosis in vitro in the presence of both recombinant TRAIL (rTRAIL) and a suboptimal dose of actinomycin D (ACD). Coadministration of soluble TRAIL (sTRAIL) gene and ACD suppressed the metastatic liver tumors of CT-26, significantly inducing apoptosis in the tumors, while such effects were not demonstrated in mice that received either the sTRAIL gene or ACD alone. The gene therapy of sTRAIL with a suboptimal dose of an anticancer drug is a new strategy for treatment of multiple liver metastasis. (c) 2006 Elsevier Ireland Ltd. All rights reserved.